P
Proteostasis Therapeutics
Innovative CFTR modulators for cystic fibrosis treatment through advanced ex vivo screening and clinical trials
About Proteostasis Therapeutics
Proteostasis Therapeutics, Inc. is a biotechnology company focused on developing novel therapies for cystic fibrosis (CF), a genetic disease that primarily affects the lungs and other organs. The company operates in the healthcare and pharmaceutical market, targeting patients with CF, particularly those with the F508del mutation. Proteostasis employs a business model centered around research and development, advancing its proprietary CFTR modulators through clinical trials. The company generates revenue through partnerships, grants, and potential future sales of its investigational drugs. Proteostasis is currently conducting the CHOICES trial, utilizing ex vivo screening of patient-derived organoids to identify responsive patients. Their triple combination therapy includes posenacaftor (a corrector), dirocaftor (a potentiator), and nesolicaftor (an amplifier), showing promising results in Phase 2 trials. The company aims to further develop and commercialize these therapies to improve the quality of life for CF patients.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2007
- Headquarters
- Cambridge, United States
- Listing
- IPO 2016
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 61.1/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Dec 2020 | $0 | — | Yumanity Therapeutics | ↗ |
| POST IPO EQUITYOther financing | Oct 2018 | $74M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $1M | 0% | −$59M | -5900% |
| 2025 | $1M | 0% | −$59M | -5900% |
| 2024 | $1M | 0% | −$59M | -5900% |
| 2023 | $1M | 0% | −$59M | -5900% |
| 2022 | $1M | 0% | −$59M | -5900% |
| 2021 | $1M | 0% | −$59M | -5900% |
| 2020 | $1M | — | −$59M | -5900% |
Growth signals
Latest recorded traffic for Proteostasis Therapeutics is 510 monthly website visits, down 60.8% over the last three months. Proteostasis Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
NEA- HVHealthCare Ventures
F-Prime
Novartis Venture Fund
Sanofi-Genzyme BioVentures
Rock Springs Capital
Cormorant Asset Management
Other known investors5 additional known investors
Northwestern University
Yumanity Therapeutics
Avoro Capital Advisors
Eight Roads Ventures
Sanofi Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Proteostasis Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Proteostasis Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.